Can a daily cream rebuild the Skin's barrier? trial puts moisturizer to the test

NCT ID NCT07820943

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 17, 2026 · Updated 2 times

Summary

Researchers are testing a moisturizing cream in 22 adults aged 36 to 65 with moderate to severe dry skin on their lower legs. Participants apply the cream twice daily for 28 days. Dermatologists check for irritation, and instruments measure skin hydration and how well the skin barrier recovers. Participants also answer questions about how the product feels and performs.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a moisturizing cream applied to the skin
What this could lead to
If the cream works, it could offer a simple, well-tolerated option for people with moderate to severe dry skin on the legs.
What could go wrong
This is a small, short study of 22 people with no comparison group, so results may not reflect how the cream performs for everyone or over longer periods. Moisturizers can occasionally cause irritation or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 22 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female participants aged 36 to 65 years. * Participants presenting moderate to severe xerosis of the lower limbs, corresponding to grades 2 or 3 on the Overall Dry Skin Score (ODS) scale, confirmed by clinical evaluation. * Participants presenting a stratum corneum hydration index between 35 and 55 arbitrary units (AU), as measured by corneometry on the forearm during the eligibility assessment. * Participants considered healthy by the investigator, with no medical conditions or use of medications that could pose an undue risk or interfere with the study results. * Willingness to comply with all study procedures and attend the study site on the scheduled dates and times for assessments. * Ability to understand the study requirements, provide written informed consent, and sign the Informed Consent Form (ICF). Exclusion Criteria: * Pregnant or breastfeeding women, or women at risk of becoming pregnant during the study, when applicable. * Use of anti-inflammatory, immunosuppressive, antihistamine, or any other medication that, in the investigator's opinion, may interfere with skin condition assessments or study outcomes. * Presence of skin marks in the test area that may interfere with clinical or instrumental evaluations of skin reactions, including vascular malformations, scars, excessive hair growth, multiple nevi, or sunburn. * Presence of active atopic dermatitis, eczema, or other dermatoses that may interfere with evaluation of the test area. * Active localized or generalized skin diseases and/or lesions in the assessment area that, in the investigator's opinion, may compromise participation in the study. * Immunosuppression due to medication use or active disease. * Uncontrolled endocrine disorders. * Presence of significant vascular alterations in the lower limbs, such as severe venous insufficiency, significant edema, lymphedema, or ulcers that may interfere with study assessments. * Relevant medical history or current evidence of alcohol or substance abuse. * Known history of or suspected intolerance to products of the same category. * Intense sun exposure within 15 days prior to the baseline assessment. * Aesthetic or dermatological treatments within 4 weeks prior to the baseline assessment. * Procedures that may temporarily alter skin condition in the test area, such as exfoliation or hair removal, within the timeframe specified by the study protocol. * Any other condition that, in the investigator's opinion, may pose a risk to the participant, interfere with protocol compliance, or compromise the interpretation of study results.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dry skin are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Grupo Medcin

    RECRUITING

    Osasco, São Paulo, 06023-070, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.